INTEGRAGEN overview

Regulatory News: IntegraGen (FR0010908723 – ALINT) , an OncoDNA Group company specializing in the decryption of the human genome which performs interpretable genomic analyzes for academic and private laboratories and develops diagnostic tools for oncology, announced today its unaudited revenue figures for the first half of 2023. The first half of 2023 unaudited revenue amount to €5,628k, representing a decrease of 13% compared to the first half of 2022. This decrease mainly reflects...

Regulatory News: IntegraGen (FR0010908723 – ALINT), an OncoDNA Group company specializing in the decryption of the human genome which performs interpretable genomic analyzes for academic and private laboratories and develops diagnostic tools for oncology, announced today its unaudited revenue figures for the year 2022. The 2022 unaudited revenue amount to €12,592k in 2022, representing an increase of 16% compared to 2021. This growth in all activities reflects the firmness of the company's...

Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME) , IntegraGen , a company specializing in the decryption of the human genome, which carries out interpretable genomic analyzes for academic and private laboratories and develops diagnostic tools in oncology and part of OncoDNA Group, today announced its half-year results for the period ending June 30, 2022. The interim accounts were approved by the company’s Board of Directors which met on October 14 th , 2022. Bernard...

Regulatory News: IntegraGen (FR0010908723 – ALINT ), an OncoDNA Group company specializing in the decryption of the human genome which performs interpretable genomic analyzes for academic and private laboratories and develops diagnostic tools for oncology, today announced its non-audited revenue of 6,439 k€ for the first half of 2022, representing an increase of 34% compared to H1 2021. This sales growth across all of the company’s businesses reflects the strong rebound of the general...

Regulatory News: IntegraGen (Paris:ALINT), a company specializing in the decryption of the human genome, which carries out interpretable genomic analyzes for academic and private laboratories and develops diagnostic tools in oncology and part of OncoDNA Group, today announced its financial results for the year ending December 31, 2021. The annual audited accounts were approved by the company’s Board of Directors which met on April 29 th , 2022. Bernard Courtieu, CEO IntegraGen, said: “ The...

Regulatory News: IntegraGen (FR0010908723 – ALINT –Eligible PEA PME) , a company specializing in the decryption of the human genome, which performs interpretable genomic analyses for academic and private laboratories, today announced its financial results for the first half of 2020. The accounts were approved by the Board of Directors at a meeting held on 7 October 2021. Primary indicators – IN THOUSANDS OF EUROS H1 2021 H1 2020 Var. % Sales 5,014 4,706 +7% EBITDA -331 248 n.a. EBIT -447...

Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME) , a company specializing in decoding the human genome which performs interpretable genomic analyzes for academic and private laboratories, today announced its unaudited turnover for the first half of 2021. The unaudited first half turnover amounted to 4,816 k€, up 2% compared to the first half of 2020 (4,706 k€). This growth was achieved despite the sharp slowdown in general economic activity during the first half of...